

## Cambodia Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Cambodia			
<b>2. Grant number:</b> 1718-KHM-12c-X / 15-KHM-08c-Y			
<b>3. Date of Decision Letter:</b> 22 March 2018			
<b>4. Date of the Partnership Framework Agreement:</b> 15 May 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine			
<b>6. Vaccine type:</b> Pneumococcal			
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2015 -2018			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	<b>2015-2017</b>	<b>2018</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	12,620,046 <sup>3</sup>	3,888,500	16,508,546
<b>10. Vaccine introduction grant (in US\$):</b> A VIG of US\$275,500 was disbursed on 16 June 2014.			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
<b>Type of supplies to be purchased with Gavi funds each year</b>	<b>2015-2017</b>	<b>2018</b>	
Number of Pneumococcal vaccines doses		1,051,800	
Annual Amounts (US\$)	12,620,046 <sup>5</sup>	3,888,500	
<b>12. Procurement agency:</b> The country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable.			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p><b>14. Co-financing obligations:</b> Reference code: 1718-KHM-12c-X-C</p> <p>According to the co-financing policy, the country falls within the group initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds each year</th> <th>2018</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>92,100</td> </tr> <tr> <td>Number of AD syringes</td> <td>98,600</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>0</td> </tr> <tr> <td>Number of safety boxes</td> <td>1,100</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>303,872</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>318,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds each year	2018	Number of vaccine doses	92,100	Number of AD syringes	98,600	Number of re-constitution syringes	0	Number of safety boxes	1,100	Value of vaccine doses (US\$)	303,872	Total co-financing payments (US\$) (including freight)	318,000
Type of supplies to be purchased with Country funds each year	2018														
Number of vaccine doses	92,100														
Number of AD syringes	98,600														
Number of re-constitution syringes	0														
Number of safety boxes	1,100														
Value of vaccine doses (US\$)	303,872														
Total co-financing payments (US\$) (including freight)	318,000														
<p><b>15. Operational support for campaigns:</b> Not applicable</p>															
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
Reports and other information	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat														
<p><b>17. Financial clarifications:</b> Not applicable.</p>															
<p><b>18. Other conditions:</b> Not applicable.</p>															

Signed by,  
On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 March 2018